Tranylcypromine hydrochloride
Based on 9 publication(s) in Google Scholar
Tranylcypromine hydrochloride (SKF 385 hydrochloride) is an irreversible inhibitor of lysine-specific demethylase 1 (LSD1/BHC110) and monoamine oxidase (MAO). Tranylcypromine hydrochloride inhibits LSD1, MAO A and MAO B with IC50s of 20.7, 2.3 and 0.95 μM, respectively. Tranylcypromine hydrochloride can be used for the research of depression.
For research use only. We do not sell to patients.
- Purity: 99.91%
- CAS No.: 1986-47-6
- Formula: C9H12ClN
- Molecular Weight:169.66
-
Storage:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Bioactive Compound Library Max
HY-L181
-
Bioactive Compound Library
HY-L001
-
Epigenetics Compound Library
HY-L005
-
Neuronal Signaling Compound Library
HY-L013
-
FDA-Approved Drug Library
HY-L022
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
-
Reprogramming Compound Library
HY-L039
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Parkinson's Disease Compound Library
HY-L085
-
Neurodegenerative Disease-related Compound Library
HY-L086
-
Mitochondria-Targeted Compound Library
HY-L089
-
Antidepressant Compound Library
HY-L108
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Target Protein Ligand Library
HY-L129
-
Off-patent Drug Library
HY-L141
-
Metabolic Enzyme Compound Library
HY-L146
-
Highly Selective Inhibitors Library
HY-L158
-
Multi-Target Compound Library
HY-L176
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Methylation Compound Library
HY-L203
-
High-Throughput Bioactive Compound Library
HY-L205
Publications Citing Use of MedChemExpress (MCE) Tranylcypromine hydrochloride
More- Biomaterials. 2019 Feb:193:30-46. [Abstract]
- Stem Cell Res Ther. 2020 Apr 16;11(1):157. [Abstract]
- Biochem Pharmacol. 2025 Sep:239:117073. [Abstract]
- Int Immunopharmacol. 2025 Oct 10:163:115242. [Abstract]
- Int Immunopharmacol. 2025 Jun 26:159:114966. [Abstract]
- Clin Exp Med. 2025 Nov 25;26(1):33. [Abstract]
- Biol Reprod. 2020 Dec 1;103(6):1229-1237. [Abstract]
- Biochem Biophys Res Commun. 2019 May 14;512(4):852-858. [Abstract]
- Patent. US20180263995A1.
Customer Validation & Images
-
Others
-
WB
-
Cell Proliferation/Viability Assay
-
Flow Cytometry
Biological Activity
|
MAO-A 2.3 μM (IC50) |
MAO-B 0.95 μM (IC50) |
LSD1 |
Tranylcypromine hydrochlorid (50 μM-5 mM; 1 h or 12-14 h) inhibits histone and nucleosomal demethylation[1]. Tranylcypromine hydrochlorid (2 μM; 3 h) shows a specific derepression of OCT4 transcription[1]. Tranylcypromine hydrochlorid (0-100 μM; 15 min) shows IC50 values of 20.7, 2.3 and 0.95 μM for LSD1, MAO A and MAO B, respectively[2]. Tranylcypromine hydrochlorid (0-800 μM) shows Ki values of 242.7, 101.9 and 16 μM for LSD1, MAO A and MAO B, respectively[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Sf21 insect cell line
-
Concentration:50 μM, 200 μM, 1 mM and 5 mM
-
Incubation Time:12-14 hours or 1 hour
-
Result:Showed inhibitory activities of histone H3K4 demethylation and nucleosomal demethylation.
-
Cell Line:P19 EC cell line
-
Concentration:2 μM
-
Incubation Time:3 hours
-
Result:Decreased Oct4 mRNA levels.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Wild-type mice[3]
-
Dosage:3 mg/kg
-
Administration:Intraperitoneal injection; 3 mg/kg once daily for 3 days
-
Result:Significantly down-regulated LPS-stimulated microglial activation in the cortex and Hippocampus, and LPS-induced astrocyte activation only in the cortex. Reduced LPS-induced COX-2 levels in hippocampus CA1, decreased LPS-evoked IL-6 levels in the cortex and hippocampus CA1 and suppressed LPS-mediated IL-1β levels in the cortex.
-
Animal Model:5xFAD mice[3]
-
Dosage:3 mg/kg
-
Administration:Intraperitoneal injection; 3 mg/kg once daily for 7 days
-
Result:Differentially regulated microglial and astrocyte activation in this mouse model of AD.
Chemical Information
-
CAS No. 1986-47-6
-
Appearance Solid
-
Molecular Weight 169.66
-
Formula C9H12ClN
-
Color White to yellow
-
SMILES
N[C@H]1[C@H](C2=CC=CC=C2)C1.[H]Cl
-
Synonyms
SKF 385 hydrochloride
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (9)
-
Journal Impact Factor
-
Most Recent
-
Biomaterials
Chemical induced conversion of mouse fibroblasts and human adipose-derived stem cells into skeletal muscle-like cells. [Abstract]2019 Feb:193:30-46. PMID: 30554025 -
Stem Cell Res Ther
Characterisation of extraembryonic endoderm-like cells from mouse embryonic fibroblasts induced using chemicals alone. [Abstract]2020 Apr 16;11(1):157. PMID: 32299508 -
Biochem Pharmacol
Triflupromazine and tranylcypromine alleviate primary cisplatin resistance in lung adenocarcinoma by promoting LDHA-mediated AMBRA1 ubiquitination. [Abstract]2025 Sep:239:117073. PMID: 40562117
Tranylcypromine hydrochloride purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Sep:239:117073. [Abstract]
Schematic diagram of Triflupromazine and Tranylcypromine hydrochloride alleviate primary cisplatin resistance in lung adenocarcinoma by promoting LDHA-mediated AMBRA1 ubiquitination. LDHA interacts with AMBRA1 via non-metabolic enzyme functions, promoting AMBRA1 ubiquitination and degradation, which leads to cisplatin resistance by regulating the cell cycle and apoptosis.
Tranylcypromine hydrochloride purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Sep:239:117073. [Abstract]
Tranylcypromine hydrochloride (0-100 μM) significantly inhibited LDHA expression and increased AMBRA1 protein levels in resistant cell line H1838.
Tranylcypromine hydrochloride purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Sep:239:117073. [Abstract]
CCK8 assay evaluating the survival of H1838 treated with serial concentrations of cisplatin in combination with Tranylcypromine hydrochloride (0-100 μM, 48 h).
Tranylcypromine hydrochloride purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 Sep:239:117073. [Abstract]
Apoptosis analysis in H1838 cells treated with cisplatin accompanied by TRI (5 μM) and Tranylcypromine hydrochloride (50 μM) respectively for 48 h.
-
Int Immunopharmacol
Tangeretin protects the kidney from ischemia-reperfusion injury by inhibiting inflammatory response through downregulation of MAOA. [Abstract]2025 Oct 10:163:115242. PMID: 40682983 -
Int Immunopharmacol
Curcumin combined with arsenic trioxide enhances autophagy and immune surveillance to inhibit immune escape in acute myeloid leukemia. [Abstract]2025 Jun 26:159:114966. PMID: 40440957 -
Clin Exp Med
Corin: a dual inhibitor for KDM1A/HDAC1, suppresses hepatocellular carcinoma by triggering cuproptosis. [Abstract]2025 Nov 25;26(1):33. PMID: 41286164 -
Biol Reprod
2020 Dec 1;103(6):1229-1237. PMID: 32902654 -
Biochem Biophys Res Commun
Suppression of LSD1 enhances the cytotoxic and apoptotic effects of regorafenib in hepatocellular carcinoma cells. [Abstract]2019 May 14;512(4):852-858. PMID: 30929918 -
Solvent & Solubility
H2O : 100 mg/mL (589.41 mM; Need ultrasonic)
DMSO : 100 mg/mL (589.41 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (14.74 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (14.74 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Working solution concentration: 0.22 mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
Purity & Documentation
-
Data Sheet (283 KB)
-
SDS (479 KB)
- English - EN (479 KB)
- Français - FR (479 KB)
- Deutsch - DE (479 KB)
- Norwegian - NO (479 KB)
- Español - ES (479 KB)
- Swedish - SV (479 KB)
- Italian - IT (479 KB)
- Korean - KR (479 KB)
- Portuguese - PT (479 KB)
-
Handling Instructions (2659 KB)
References
[1]. Lee MG, et al. Histone H3 lysine 4 demethylation is a target of nonselective antidepressive medications. Chem Biol. 2006 Jun;13(6):563-7. [Content Brief]
[2]. Schmidt DM, McCafferty DG. trans-2-Phenylcyclopropylamine is a mechanism-based inactivator of the histone demethylase LSD1. Biochemistry. 2007 Apr 10;46(14):4408-16. [Content Brief]
[3]. Park H, et al. The MAO Inhibitor Tranylcypromine Alters LPS- and Aβ-Mediated Neuroinflammatory Responses in Wild-type Mice and a Mouse Model of AD. Cells. 2020 Aug 28;9(9):1982. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O / DMSO | 1 mM | 5.8941 mL | 29.4707 mL | 58.9414 mL | 147.3535 mL |
| 5 mM | 1.1788 mL | 5.8941 mL | 11.7883 mL | 29.4707 mL | |
| 10 mM | 0.5894 mL | 2.9471 mL | 5.8941 mL | 14.7354 mL | |
| 15 mM | 0.3929 mL | 1.9647 mL | 3.9294 mL | 9.8236 mL | |
| 20 mM | 0.2947 mL | 1.4735 mL | 2.9471 mL | 7.3677 mL | |
| 25 mM | 0.2358 mL | 1.1788 mL | 2.3577 mL | 5.8941 mL | |
| 30 mM | 0.1965 mL | 0.9824 mL | 1.9647 mL | 4.9118 mL | |
| 40 mM | 0.1474 mL | 0.7368 mL | 1.4735 mL | 3.6838 mL | |
| 50 mM | 0.1179 mL | 0.5894 mL | 1.1788 mL | 2.9471 mL | |
| 60 mM | 0.0982 mL | 0.4912 mL | 0.9824 mL | 2.4559 mL | |
| 80 mM | 0.0737 mL | 0.3684 mL | 0.7368 mL | 1.8419 mL | |
| 100 mM | 0.0589 mL | 0.2947 mL | 0.5894 mL | 1.4735 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Tranylcypromine hydrochloride Related Classifications
HY-17447A Related Classifications
Powered by Bioz